345 related articles for article (PubMed ID: 27426859)
1. Current and emerging approaches for assessing von Willebrand disease in 2016.
Federici AB
Int J Lab Hematol; 2016 May; 38 Suppl 1():41-9. PubMed ID: 27426859
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
4. Clinical and laboratory diagnosis of VWD.
Federici AB
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):524-30. PubMed ID: 25696905
[TBL] [Abstract][Full Text] [Related]
5. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
[TBL] [Abstract][Full Text] [Related]
6. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
7. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
Michiels JJ; Gadisseur A; Budde U; Berneman Z; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Semin Thromb Hemost; 2005 Nov; 31(5):577-601. PubMed ID: 16276467
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a von Willebrand factor three test panel and chemiluminescent-based assay system for identification of, and therapy monitoring in, von Willebrand disease.
Favaloro EJ; Mohammed S
Thromb Res; 2016 May; 141():202-11. PubMed ID: 26743192
[TBL] [Abstract][Full Text] [Related]
9. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
10. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
11. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
12. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.
Michiels JJ; van de Velde A; van Vliet HH; van der Planken M; Schroyens W; Berneman Z
Semin Thromb Hemost; 2002 Apr; 28(2):111-32. PubMed ID: 11992235
[TBL] [Abstract][Full Text] [Related]
13. Von Willebrand's disease: case report and review of literature.
Echahdi H; El Hasbaoui B; El Khorassani M; Agadr A; Khattab M
Pan Afr Med J; 2017; 27():147. PubMed ID: 28904675
[TBL] [Abstract][Full Text] [Related]
14. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
Castaman G; Federici AB; Rodeghiero F; Mannucci PM
Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
[TBL] [Abstract][Full Text] [Related]
15. Von Willebrand factor collagen-binding (activity) assay in the diagnosis of von Willebrand disease: a 15-year journey.
Favaloro EJ
Semin Thromb Hemost; 2002 Apr; 28(2):191-202. PubMed ID: 11992242
[TBL] [Abstract][Full Text] [Related]
16. Developments in the diagnostic procedures for von Willebrand disease.
De Jong A; Eikenboom J
J Thromb Haemost; 2016 Mar; 14(3):449-60. PubMed ID: 26714181
[TBL] [Abstract][Full Text] [Related]
17. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
Lippi G; Franchini M; Salvagno GL; Montagnana M; Poli G; Guidi GC
J Thromb Thrombolysis; 2008 Oct; 26(2):150-3. PubMed ID: 17786534
[TBL] [Abstract][Full Text] [Related]
18. How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types.
Favaloro EJ; Mohammed S; Vong R; Oliver S; Brennan Y; Favaloro JW; Curnow J
Haemophilia; 2021 Jan; 27(1):137-148. PubMed ID: 33215808
[TBL] [Abstract][Full Text] [Related]
19. Laboratory assessment as a critical component of the appropriate diagnosis and sub-classification of von Willebrand's disease.
Favaloro EJ
Blood Rev; 1999 Dec; 13(4):185-204. PubMed ID: 10741895
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]